| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20050139 | HPV | ENSG00000070961.17 | protein_coding | ATP2B1 | No | No | 490 | P20020 |
| TVIS20031312 | HPV | ENSG00000070961.17 | protein_coding | ATP2B1 | No | No | 490 | P20020 |
| TVIS44031494 | HTLV-1 | ENSG00000070961.17 | protein_coding | ATP2B1 | No | No | 490 | P20020 |
| TVIS44015290 | HTLV-1 | ENSG00000070961.17 | protein_coding | ATP2B1 | No | No | 490 | P20020 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ATP2B1 |
|---|---|
| DrugBank ID | DB01159 |
| Drug Name | Halothane |
| Target ID | BE0009972 |
| UniProt ID | P23634 |
| Regulation Type | inhibitor |
| PubMed IDs | 7499320; 10814537 |
| Citations | Lopez MM, Kosk-Kosicka D: How do volatile anesthetics inhibit Ca(2+)-ATPases? J Biol Chem. 1995 Nov 24;270(47):28239-45.@@Brennan LK, Froemming GR, Ohlendieck K: Effect of halothane on the oligomerization of the sarcoplasmic reticulum Ca(2+)-ATPase. Biochem Biophys Res Commun. 2000 May 19;271(3):770-6. doi: 10.1006/bbrc.2000.2688. |
| Groups | Approved; Vet_approved |
| Direct Classification | Organofluorides |
| SMILES | [H]C(Cl)(Br)C(F)(F)F |
| Pathways | |
| PharmGKB | PA449845 |
| ChEMBL | CHEMBL931 |
